**PBS Transparency and Efficiencies Subgroup**

**Communique**

**July – December 2020**

The PBS Transparency and Efficiencies Subgroup met once during the second half of 2020. Attendees included representatives from the Generic and Biosimilar Medicines Association (GBMA), Medicines Australia (MA), industry and the Department of Health (the department).

At the August 2020 meeting, members focused their discussion on the proposed fees and activities associated with deed management, understanding the rationale for the fee increases and clarification that a separate fee applies to each list management application, including in instances where multiple applications are made in a single request relating to the same drug and for the same therapy (e.g. for two different strengths). Members noted that the revised 2020-21 Cost Recovery Implementation Statement (CRIS) would be circulated to members prior to public consultation in September 2020. The CRIS was reviewed for 1 July 2021, with public consultation undertaken prior to publication.

Members noted that pending Government approval, the Department was working towards a   
1 January 2021 implementation date for Stage 2 PBS process improvements. The next review of the activity based cost model will be undertaken in 2022, twelve months post implementation of Stage 2 changes.

The PBS Transparency and Efficiencies Subgroup will continue to meet in 2021 as needed.